These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29105629)

  • 1. Designing and molecular docking of cyclic peptides against HCV NS3 protease.
    Masoud MS; Bukhari SA; Qasim M; Naqvi SAR; Ashfaq UA
    Pak J Pharm Sci; 2017 Sep; 30(5(Supplementary)):1965-1969. PubMed ID: 29105629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potential inhibitors for HCV NS3 genotype 4a by combining protein-ligand interaction fingerprint, 3D pharmacophore, docking, and dynamic simulation.
    El-Hasab MAE; El-Bastawissy EE; El-Moselhy TF
    J Biomol Struct Dyn; 2018 May; 36(7):1713-1727. PubMed ID: 28531373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.
    Tsantrizos YS; Bolger G; Bonneau P; Cameron DR; Goudreau N; Kukolj G; LaPlante SR; Llinàs-Brunet M; Nar H; Lamarre D
    Angew Chem Int Ed Engl; 2003 Mar; 42(12):1356-60. PubMed ID: 12671967
    [No Abstract]   [Full Text] [Related]  

  • 4. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques.
    Wei HY; Lu CS; Lin TH
    J Mol Graph Model; 2008 Apr; 26(7):1131-44. PubMed ID: 18024210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based drug design of novel peptidomimetic cellulose derivatives as HCV-NS3 protease inhibitors.
    Saleh NA; Elshemey WM
    Life Sci; 2017 Oct; 187():58-63. PubMed ID: 28842311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico screening for potent inhibitors against the NS3/4A protease of hepatitis C virus.
    Meeprasert A; Rungrotmongkol T; Li MS; Hannongbua S
    Curr Pharm Des; 2014; 20(21):3465-77. PubMed ID: 24001230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-silico identification and evaluation of plant flavonoids as dengue NS2B/NS3 protease inhibitors using molecular docking and simulation approach.
    Qamar MT; Ashfaq UA; Tusleem K; Mumtaz A; Tariq Q; Goheer A; Ahmed B
    Pak J Pharm Sci; 2017 Nov; 30(6):2119-2137. PubMed ID: 29175781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of ketoamide inhibitors on HCV NS3/4A protease target: molecular docking studies.
    Wadood A; Riaz M; Jamal SB; Shah M
    Mol Biol Rep; 2014 Jan; 41(1):337-45. PubMed ID: 24234753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
    Ezat AA; Elshemey WM
    Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.
    Bachmetov L; Gal-Tanamy M; Shapira A; Vorobeychik M; Giterman-Galam T; Sathiyamoorthy P; Golan-Goldhirsh A; Benhar I; Tur-Kaspa R; Zemel R
    J Viral Hepat; 2012 Feb; 19(2):e81-8. PubMed ID: 22239530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease.
    Mukhametov A
    Curr Top Med Chem; 2016; 16(12):1351-61. PubMed ID: 26585936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacophore feature prediction and molecular docking approach to identify novel anti-HCV protease inhibitors.
    Venkatesan A; Rambabu M; Jayanthi S; Febin Prabhu Dass J
    J Cell Biochem; 2018 Jan; 119(1):960-966. PubMed ID: 28691304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico identification and evaluation of leads for the simultaneous inhibition of protease and helicase activities of HCV NS3/4A protease using complex based pharmacophore mapping and virtual screening.
    Wadood A; Riaz M; Uddin R; Ul-Haq Z
    PLoS One; 2014; 9(2):e89109. PubMed ID: 24551230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric inhibitors of the NS3 protease from the hepatitis C virus.
    Abian O; Vega S; Sancho J; Velazquez-Campoy A
    PLoS One; 2013; 8(7):e69773. PubMed ID: 23936097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs.
    Bilodeau F; Bailey MD; Bhardwaj PK; Bordeleau J; Forgione P; Garneau M; Ghiro E; Gorys V; Halmos T; Jolicoeur ES; Leblanc M; Lemke CT; Naud J; O'Meara J; White PW; Llinàs-Brunet M
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4267-71. PubMed ID: 23735741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.